Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study

Executive Summary

While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.

Advertisement

Related Content

After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD
Nature Cell’s Stem Cell Alzheimer’s Therapy Advances Amid Failures
Phase III Will Be Real Test For vTv's Resurrected Alzheimer's Drug
Alzheimer's Disease: Defusing The Bomb By 2025
Alzheimer's Disease: Learning the Lessons Of The Past To Prepare For The Future
Private Neurology Companies: Back In The Saddle Again
Tau Interest Rising As Janssen Licenses AC Immune Alzheimer’s Vaccine

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097010

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel